Insmed shares up on FDA priority review for lung disease drug
Insmed Inc shares rose 2% premarket to $122.41 after the U.S. Food and Drug Administration granted priority review for its Arikayce drug to treat Mycobacterium avium complex lung disease. Full approval could expand its use to newly diagnosed patients. The FDA set a target decision date of Jan. 28, 2027. A late-stage st